MicroPort Heart Care

MicroPort Heart Care Medical Technology Co., Ltd. (02160.HK, referred to as "Heart Care Medical") is an advanced medical device enterprise in China, focusing on the research, development, and commercialization of innovative transcatheter and surgical solutions for structural heart disease. As a subsidiary of MicroPort Scientific Corporation (00853.HK), Heart Care Medical originated from its heart valve pre-research project established in 2009, was incorporated as "Shanghai MicroPort Heart Care Medical Technology Co., Ltd." in 2015, and was listed on the Main Board of the Hong Kong Stock Exchange in February 2021.

Heart Care Medical's VitaFlow® series transcatheter aortic valve implantation (TAVI) products, with their unique product design and excellent clinical performance, have entered nearly 500 core hospitals in China. Its second-generation TAVI product, VitaFlow Liberty®, is the world's first commercially available electric retrievable TAVI product. In addition to TAVI products, the company has also established a strategic R&D layout covering transcatheter mitral valve treatment products, transcatheter tricuspid valve treatment products, surgical valve products, and surgical accessories, through independent R&D and joint development with global partners. At present, Heart Care Medical's products have fully entered the international market, covering 4 countries overseas including Argentina, Thailand, Colombia, and Brazil. The company is fully advancing the process of obtaining EU CE certification for its core products, and actively laying out overseas markets such as India, South Korea, Russia, Mexico, and Chile, continuously expanding its global influence.